Sanofi (SNY) Stock Forecast & Price Target

$46.75 +1.11 (+2.43%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$46.18 -0.57 (-1.22%)

As of 08/1/2025 07:43 PM Eastern

Sanofi - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
2

Buy
6

Based on 8 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 2 have given a hold rating, 3 have given a buy rating, and 3 have given a strong buy rating for SNY.

Consensus Price Target

$62.00
32.62% Upside

According to the 8 analysts' twelve-month price targets for Sanofi, the average price target is $62.00. The highest price target for SNY is $65.00, while the lowest price target for SNY is $56.00. The average price target represents a forecasted upside of 32.62% from the current price of $46.75.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SNY Analyst Ratings Over Time

Type	Current Forecast 8/2/24 to 8/2/25	1 Month Ago 7/3/24 to 7/3/25	3 Months Ago 5/4/24 to 5/4/25	1 Year Ago 8/3/23 to 8/2/24
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$62.00	$61.50	$63.33	$57.50
Forecasted Upside	32.62% Upside	25.81% Upside	14.24% Upside	8.39% Upside
Consensus Rating	Buy	Buy	Buy	Hold

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	S&P 500
Consensus Rating Score	3.13	2.81	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	32.62% Upside	10,285.41% Upside	14.62% Upside
News Sentiment Rating	Positive News See Recent SNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/2/2025	Barclays 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight
6/3/2025	Guggenheim 2 of 5 stars		Reiterated Rating	Buy ➝ Buy
6/2/2025	Morgan Stanley 3 of 5 stars	Sarita Kapila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$56.00	+11.01%
4/28/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/15/2025	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00	+27.28%
3/21/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00	+12.48%
1/30/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Cespedes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/30/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
9/17/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$55.00 ➝ $60.00	+13.92%
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
10/30/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:41 AM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 31, 2025. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi recently reported earnings per share (EPS) of $0.94, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
The current stock price is around $49.25, which is near its 52-week low, suggesting a potential buying opportunity for investors looking for value.
Sanofi has a solid market capitalization of approximately $123.53 billion, reflecting its stability and presence in the healthcare sector.
The company has a low debt-to-equity ratio of 0.16, indicating a conservative approach to leverage and financial risk, which can be appealing to risk-averse investors.
Analysts have recently upgraded their ratings on Sanofi, with several firms issuing "buy" or "strong-buy" recommendations, suggesting positive sentiment and potential for stock appreciation.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Sanofi's quarterly revenue was down 11.0% year-over-year, which raises concerns about its growth trajectory and ability to maintain sales levels.
The company has a quick ratio of 0.69, which is below 1, indicating potential liquidity issues that could affect its ability to meet short-term obligations.
Despite recent upgrades, the overall market sentiment can be volatile, and external factors such as regulatory changes in the healthcare sector could impact Sanofi's performance.
Sanofi's net margin of 14.56% suggests that while it is profitable, there may be room for improvement in cost management and operational efficiency.
The stock has a beta of 0.48, indicating lower volatility compared to the market, which may limit potential gains during bullish market conditions.

SNY Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $62.00, with a high forecast of $65.00 and a low forecast of $56.00.
: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 2 hold ratings, 3 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNY shares.
: According to analysts, Sanofi's stock has a predicted upside of 32.62% based on their 12-month stock forecasts.
: Sanofi has been rated by research analysts at Barclays, Guggenheim, and Morgan Stanley in the past 90 days.
: Analysts like Sanofi more than other "medical" companies. The consensus rating for Sanofi is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:SNY) was last updated on 8/2/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target